Physician profile
Alan Gordon Stein
NPI 1134168131
$2,311.89
in general payments reported to CMS, 2019-2025
17 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $20.26 · 2021: $208 · 2022: $605 · 2023: $182 · 2024: $308 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $495.29 | 2019-2025 | Fintepla, Briviact |
| Sk Life Science, INC. | $423.01 | 2022-2024 | Xcopri |
| Medtronic USA, INC. | $252.52 | 2019 | |
| Jazz Pharmaceuticals INC. | $242.28 | 2022-2025 | |
| Nuvasive, INC. | $225.21 | 2022 | |
| Neuropace, INC. | $149.67 | 2019 | |
| Greenwich Biosciences, INC. | $132.92 | 2019 | |
| Depuy Synthes Sales INC. | $115.74 | 2019 | |
| Pfizer INC. | $48.85 | 2025 | |
| Livanova USA, INC. | $35.56 | 2020-2022 | |
| Medtronic, INC. | $34.47 | 2021 | |
| Chiesi USA, INC. | $29.12 | 2023 | Cleviprex |
| Tanabe Pharma America, INC. | $27.47 | 2023 | |
| Biogen, INC. | $27.28 | 2025 | Vumerity |
| Abbvie INC. | $26.05 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $23.31 | 2025 | Bafiertam |
| Zogenix INC. | $23.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.